Pregabalin Capsule
Product Images NDC 70518-3346

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-3346). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin 300 mg oral capsules packaging label showing quantity of 60 capsules. Label indicates Schedule C-V controlled substance and is for prescription use only (RX ONLY). Distributed by RemedyRepack Inc. The label includes storage instructions, repackaging information, and manufacturer details for Novadoz Pharmaceuticals LLC in Piscataway, NJ.*

FDA Label Image

Equation (Pregabain Gault Equation)

A pharmacokinetic formula panel displaying the creatinine clearance (CLCr) calculation. It shows the equation using age, weight, and serum creatinine levels with an adjustment factor for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 25 mg, 100 mg, and 200 mg doses given three times a day compared to placebo. The y-axis shows the percent of patients improved, and the x-axis shows the percent improvement in pain from baseline. Multiple lines represent different doses and placebo, showing their respective efficacy trends.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A line graph comparing the percent of patients improved at various levels of percent improvement in pain from baseline for Pregabalin 100 mg three times a day versus placebo. The x-axis shows percent improvement in pain from greater than 0% to 100%, while the y-axis represents percent of patients improved, ranging from 0 to 100%. The graph features two distinct lines: a dashed line for Pregabalin and a dotted line for placebo, illustrating differences in patient improvement rates between the two groups.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A cumulative distribution graph showing the percent of patients improved versus percent improvement in pain from baseline. Four lines represent Pregabalin 300 mg, 150 mg, and 75 mg taken two times a day, and placebo, illustrating varying degrees of patient improvement associated with each treatment.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A graph showing the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares three treatments: Pregabalin 200 mg three times a day (solid line), Pregabalin 100 mg three times a day (dashed line), and placebo (dotted line). Both Pregabalin doses show higher patient improvement percentages across varying pain improvement levels compared to placebo.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The y-axis represents the percent of patients improved, and the x-axis represents percent improvement in pain from baseline, ranging from greater than 0 to 100%.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart labeled Study E1 and Study E3 showing responder rates (%) for different daily dosages of Pregabalin compared to placebo. Study E1 presents data for placebo, 50 mg, 150 mg, 300 mg, and 600 mg per day dosed twice daily (BID). Study E3 compares placebo with 600 mg per day dosed BID and three times daily (TID). The Y-axis shows responder rates from 0% to 60%, with bars indicating increasing response percentages across Pregabalin doses versus placebo.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph depicting seizure reduction as median percent change from baseline versus dose in mg/day. The graph includes four data series labeled Stukly E1BID, E2BID, E3BID, and E3TID, showing increasing seizure reduction with higher doses up to 600 mg/day. Significant p-values are indicated for various points on the graph.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line chart comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and placebo. The chart includes four lines representing these groups, showing their respective trends in patient improvement percentages across different pain improvement levels.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart comparing Pregabalin and Placebo groups over 180 days. The y-axis represents the estimated percentage of subjects without LTR (long-term response), ranging from 0% to 100%, and the x-axis shows time in days from 0 to 180. Two lines depict the decline in percentage over time for Pregabalin (solid line) and Placebo (dashed line).*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12 BOCF for Pregabalin versus Placebo. The y-axis shows percent of subjects improved from 0 to 100%, while the x-axis shows percent improvement from baseline to Week 12. The solid line represents Pregabalin, and the dotted line represents Placebo, with Pregabalin showing higher percentages of subject improvement across most of the range.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line chart comparing the percent of subjects improved from baseline to week 16 for Pregabalin versus Placebo. The x-axis represents the percent improved from 0% to 100%, while the y-axis shows the percent of subjects improved from 0% to 100%. Pregabalin is represented by a solid line and Placebo by a dotted line.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure diagram of pregabalin, showing its molecular composition and arrangement of atoms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.